• 1
    Patrono C, Garcia-Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 237383.
  • 2
    Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with antiplatelet inhibitory drugs. Blood 1987; 69: 1806.
  • 3
    Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S64S.
  • 4
    Hankle GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 60617.
  • 5
    Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 37990.
  • 6
    Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 16505.
  • 7
    Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg G, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, Hamm C, Hu T, Fox KAA, Topol EJ. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid. Determinants and effects on cardiovascular risk. Circulation 2008; 118: 170512.
  • 8
    Russo I, Frascaroli C, Mattiello L, Viretto M, Barale C, Doronzo G, DiMartino L, Trovati M, Anfossi G. Aspirin resistance subjects present a pro-inflammatory milieu with an increased oxidative stress: in these conditions, high glucose fails to influence platelet response to agonists. Diabetologia 2011; 54(Suppl. 1): S36.
  • 9
    Ames PRJ, Batuca JR, Muncy IJ, Garcia De La Torre I, Pascoe-Gonzales S, Guyer K, Matsuura E, Lopez LR. Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus. Thromb Res 2012; doi:10.1016/j.thromres.2012.03.025.